These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21575258)

  • 81. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
    Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
    Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
    [TBL] [Abstract][Full Text] [Related]  

  • 82. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
    Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
    Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 84. CD81 is a candidate tumor suppressor gene in human gastric cancer.
    Yoo TH; Ryu BK; Lee MG; Chi SG
    Cell Oncol (Dordr); 2013 Apr; 36(2):141-53. PubMed ID: 23264205
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Map2k4δ - identification and functional characterization of a novel Map2k4 splice variant.
    Haeusgen W; Tueffers L; Herdegen T; Waetzig V
    Biochim Biophys Acta; 2014 May; 1843(5):875-84. PubMed ID: 24487067
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Methylation profiles of hereditary and sporadic ovarian cancer.
    Bol GM; Suijkerbuijk KP; Bart J; Vooijs M; van der Wall E; van Diest PJ
    Histopathology; 2010 Sep; 57(3):363-70. PubMed ID: 20840667
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer.
    Bondurant AE; Huang Z; Whitaker RS; Simel LR; Berchuck A; Murphy SK
    Gynecol Oncol; 2011 Dec; 123(3):581-7. PubMed ID: 21955482
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
    Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors.
    Ichikawa Y; Yoshida S; Koyama Y; Hirai M; Ishikawa T; Nishida M; Tsunoda H; Kubo T; Miwa M; Uchida K
    Int J Cancer; 1996 Dec; 69(6):466-70. PubMed ID: 8980248
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Mobile element insertions and associated structural variants in longitudinal breast cancer samples.
    Steely CJ; Russell KL; Feusier JE; Qiao Y; Tavtigian SV; Marth G; Jorde LB
    Sci Rep; 2021 Jun; 11(1):13020. PubMed ID: 34158539
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pitfalls in experimental designs for characterizing the transcriptional, methylational and copy number changes of oncogenes and tumor suppressor genes.
    Zhang Y; Xia J; Zhang Y; Qin Y; Yang D; Qi L; Zhao W; Wang C; Guo Z
    PLoS One; 2013; 8(3):e58163. PubMed ID: 23472150
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
    Teng DH; Perry WL; Hogan JK; Baumgard M; Bell R; Berry S; Davis T; Frank D; Frye C; Hattier T; Hu R; Jammulapati S; Janecki T; Leavitt A; Mitchell JT; Pero R; Sexton D; Schroeder M; Su PH; Swedlund B; Kyriakis JM; Avruch J; Bartel P; Wong AK; Tavtigian SV
    Cancer Res; 1997 Oct; 57(19):4177-82. PubMed ID: 9331070
    [TBL] [Abstract][Full Text] [Related]  

  • 96. miR-4486 inhibits colorectal cancer proliferation via targeting MAP2K4 to inhibit the activation of the p38MAPK/JNK signaling.
    Wang W; Chen L; Xu F; Chen R; Li Q; Zou L; Hu H; Zhu W
    Heliyon; 2024 Nov; 10(21):e38926. PubMed ID: 39512455
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    J Ovarian Res; 2023 Jul; 16(1):141. PubMed ID: 37460928
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer.
    Adamson AW; Ding YC; Steele L; Leong LA; Morgan R; Wakabayashi MT; Han ES; Dellinger TH; Lin PS; Hakim AA; Wilczynski S; Warden CD; Tao S; Bedell V; Cristea MC; Neuhausen SL
    Res Sq; 2023 Feb; ():. PubMed ID: 36865331
    [No Abstract]   [Full Text] [Related]  

  • 99. The circular RNA expression profile in ovarian serous cystadenocarcinoma reveals a complex circRNA-miRNA regulatory network.
    Zhuang M; Zhao J; Wu J; Fu S; Han P; Song X
    BMC Med Genomics; 2021 Dec; 14(Suppl 2):276. PubMed ID: 34857007
    [TBL] [Abstract][Full Text] [Related]  

  • 100. MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis.
    Liu S; Huang J; Zhang Y; Liu Y; Zuo S; Li R
    Aging (Albany NY); 2019 Nov; 11(22):10697-10710. PubMed ID: 31761784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.